NASDAQ: CPRX
Catalyst Pharmaceuticals Inc Stock

$23.27+0.01 (+0.04%)
Updated Feb 14, 2025
CPRX Price
$23.27
Fair Value Price
N/A
Market Cap
$2.78B
52 Week Low
$13.49
52 Week High
$24.64
P/E
18.62x
P/B
4.2x
P/S
5.14x
PEG
0.7x
Dividend Yield
N/A
Revenue
$460.48M
Earnings
$142.80M
Gross Margin
86.3%
Operating Margin
41%
Profit Margin
31%
Debt to Equity
0.17
Operating Cash Flow
$225M
Beta
1.27
Next Earnings
Feb 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A

CPRX Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CPRX's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CPRX
Ranked
#17 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CPRX news, forecast changes, insider trades & much more!

CPRX News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CPRX ($23.27) is trading above its intrinsic value of $17.60, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CPRX is good value based on its earnings relative to its share price (18.62x), compared to the US market average (37.92x)
P/E vs Market Valuation
CPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CPRX due diligence checks available for Premium users.

Valuation

CPRX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
18.62x
Industry
-169.22x
Market
37.92x
CPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CPRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

CPRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.2x
Industry
4.77x
CPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CPRX price to earnings growth (PEG)

For valuing profitable companies with growth potential

CPRX is good value based... subscribe to Premium to read more.
PEG Value Valuation

CPRX's financial health

Profit margin

Revenue
$128.7M
Net Income
$43.9M
Profit Margin
34.1%
CPRX's Earnings (EBIT) of $188.79M... subscribe to Premium to read more.
Interest Coverage Financials
CPRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$772.0M
Liabilities
$111.1M
Debt to equity
0.17
CPRX's short-term assets ($539.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CPRX's short-term assets ($539.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$72.9M
Investing
-$259.0k
Financing
-$6.0M
CPRX's operating cash flow ($224.58M)... subscribe to Premium to read more.
Debt Coverage Financials

CPRX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CPRXB$2.78B+0.04%18.62x4.20x
MLTXD$2.76B-0.89%-34.02x5.66x
MRUSC$2.75B-0.25%-10.18x3.91x
VCELB$2.82B+0.49%815.57x10.94x
BEAMD$2.68B+13.25%-20.51x3.39x

Catalyst Pharmaceuticals Stock FAQ

What is Catalyst Pharmaceuticals's quote symbol?

(NASDAQ: CPRX) Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol CPRX. Catalyst Pharmaceuticals stock quotes can also be displayed as NASDAQ: CPRX.

If you're new to stock investing, here's how to buy Catalyst Pharmaceuticals stock.

What is the 52 week high and low for Catalyst Pharmaceuticals (NASDAQ: CPRX)?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's 52-week high was $24.64, and its 52-week low was $13.49. It is currently -5.56% from its 52-week high and 72.5% from its 52-week low.

How much is Catalyst Pharmaceuticals stock worth today?

(NASDAQ: CPRX) Catalyst Pharmaceuticals currently has 119,273,436 outstanding shares. With Catalyst Pharmaceuticals stock trading at $23.27 per share, the total value of Catalyst Pharmaceuticals stock (market capitalization) is $2.78B.

Catalyst Pharmaceuticals stock was originally listed at a price of $6.10 in Nov 8, 2006. If you had invested in Catalyst Pharmaceuticals stock at $6.10, your return over the last 18 years would have been 281.48%, for an annualized return of 7.72% (not including any dividends or dividend reinvestments).

How much is Catalyst Pharmaceuticals's stock price per share?

(NASDAQ: CPRX) Catalyst Pharmaceuticals stock price per share is $23.27 today (as of Feb 14, 2025).

What is Catalyst Pharmaceuticals's Market Cap?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's market cap is $2.78B, as of Feb 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Catalyst Pharmaceuticals's market cap is calculated by multiplying CPRX's current stock price of $23.27 by CPRX's total outstanding shares of 119,273,436.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.